Browse drugs

…ion of patients achieving SRI-4, BICLA, or LLDAS responses with upadacitinib vs placebo based on changes in MCID for (A) FACIT-fatigue, (B) …

…ons, delivery device, and the flow for the patient‘s condition. Oxygen treatment when stopped, should be discontinued on the prescribi…

….0 mmol/L).Results Few hypoglycemic events occurred (none after dextrose, two after lactose, one after galactose, and four after placebo…

…Objective Radiotherapy modalities such as iodine-125 (I 125) and ruthenium-106 (Ru106) brachytherapy and proton beam…

…equivalence margins, confirming therapeutic equivalence between FYB203 and reference aflibercept. Safety and immunogenicity profiles w…

… a shift from oxidative to glycolytic metabolism.In conclusion, fumarate derivatives activate key Nrf2-dependent antioxidant pathways and reveal a n…

…isease Activity Index (SLEDAI) at baseline was 6.7, with a mean prednisone dose of 6 mg/day. DORIS remission at 6 months was 71% for the c…

…and HTPs: WS3, WS23, WS5, WS27, isopulegol, menthyl lactate and monomenthyl succinate. WS3 and WS23 were the predominant coolants in cigarettes and H…

…their proven efficacy, there remains a gap in the initiation of Sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus patients with evidence of coronary …

…nd inversely with ABCA1-CEC (p-for-interaction=0.010) in males. Estrone, but not estradiol, was inversely associated with cardiovascula…

…strict nurses were with administering fentanyl. As subcutaneous fentanyl is adopted more widely, a follow-up audit at regional level is …

…k M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. New Englan…